Evidence map›Paper›PMID 34171435›Full record

ArticleJournal of hepatology2021

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine.

Daniel Clayton-Chubb, Daniel Schneider, Elliot Freeman, William Kemp, Stuart K Roberts

Abstract readLetterComment
In one paragraph

Article in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. An overview of HLA variants in COVID-19 vaccine-induced autoimmunity.International journal of molecular epidemiology and genetics · 2025
    Review
  9. Review
  10. Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 vaccine.The journal of allergy and clinical immunology. Global · 2024
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Autoimmune liver diseases and SARS-CoV-2.World journal of gastroenterology · 2023
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Daniel Clayton-ChubbDepartment of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia. Electronic address: d.clayton-chubb@alfred.org.au.
Daniel SchneiderDepartment of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia.
Elliot FreemanDepartment of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia.
William KempDepartment of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia; Central Clinical School, Department of Medicine, Monash University, Melbourne, Victoria, Australia.
Stuart K RobertsDepartment of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia; Central Clinical School, Department of Medicine, Monash University, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Hepatitis, AutoimmuneVaccinesChAdOx1 nCoV-19COVID-19 VaccinesHumansChAdOx1 nCoV-19COVID-19 VaccinesVaccinesautoimmune hepatitisCOVID-19 vaccineimmune mediated

Identifiers

PMID34171435
PMCPMC8219312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.